AI Engines For more Details: Perplexity Kagi Labs You
Lowering Blood Pressure: Terazosin works by relaxing blood vessels, which allows blood to flow more easily, resulting in a reduction of blood pressure. It is effective in treating both systolic and diastolic hypertension.
Improving Urinary Symptoms: Terazosin is also used to treat urinary symptoms associated with benign prostatic hyperplasia (BPH), such as difficulty urinating, weak urine stream, and frequent urination, by relaxing the muscles in the prostate and bladder neck.
Dosage and Administration: Terazosin is usually taken orally, once daily, with or without food. The dosage may be adjusted by a healthcare provider based on the individual's response to treatment and blood pressure goals.
Side Effects: Common side effects of terazosin may include dizziness, lightheadedness, drowsiness, headache, weakness, nasal congestion, and swelling of the ankles or feet. These side effects are usually mild and transient but may require medical attention if they persist or worsen.
Orthostatic Hypotension: Terazosin can cause a sudden drop in blood pressure upon standing up from a sitting or lying position, known as orthostatic hypotension. Patients should be advised to rise slowly from a lying or sitting position to minimize the risk of falls or fainting.
First-Dose Hypotension: Initiation of terazosin therapy, or dosage increases, may result in first-dose hypotension, characterized by a sudden drop in blood pressure after the first dose. To reduce the risk of first-dose hypotension, the initial dose of terazosin is usually started at a low dose and gradually titrated upwards.
Cardiovascular Effects: Terazosin may cause palpitations, tachycardia (rapid heartbeat), and other cardiovascular effects in some patients. Patients with pre-existing cardiovascular conditions should use terazosin with caution and under the supervision of a healthcare provider.
Drug Interactions: Terazosin may interact with other medications, such as phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil), alpha-adrenergic blockers, and antihypertensive drugs, potentially leading to additive hypotensive effects or other adverse reactions. Patients should inform their healthcare provider about all medications they are taking to avoid potential drug interactions.
Prostate Cancer Screening: Terazosin is not indicated for the treatment of prostate cancer. Men receiving terazosin therapy for BPH should undergo regular prostate cancer screening as recommended by their healthcare provider.
Pregnancy and Lactation: Terazosin is not recommended for use during pregnancy or lactation unless the potential benefits outweigh the risks. Pregnant or breastfeeding women should consult their healthcare provider before taking terazosin.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.2 | 0.1 | 1 |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.2 | |
| Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | |
| Allergies | 0 | 0.1 | 0 |
| Allergy to milk products | 0.1 | 0.1 | 0 |
| Alzheimer's disease | 0.1 | 0.6 | -5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0 | |
| Ankylosing spondylitis | 0.1 | 0.1 | 0 |
| Anorexia Nervosa | 0.2 | -0.2 | |
| Asthma | 0.3 | 0.2 | 0.5 |
| Atherosclerosis | 0.1 | 0.2 | -1 |
| Atrial fibrillation | 0.1 | 0.1 | 0 |
| Autism | 0.4 | 0.3 | 0.33 |
| Autoimmune Disease | 0.2 | -0.2 | |
| benign prostatic hyperplasia | 0.1 | -0.1 | |
| Bipolar Disorder | 0.1 | 0.3 | -2 |
| Brain Trauma | 0.2 | -0.2 | |
| Carcinoma | 0.1 | 0.1 | 0 |
| Celiac Disease | 0.1 | 0.1 | 0 |
| Cerebral Palsy | 0.1 | 0.2 | -1 |
| Chronic Fatigue Syndrome | 0.2 | 0.2 | 0 |
| Chronic Kidney Disease | 0.1 | 0.2 | -1 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0 | 0.2 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.2 | -0.2 | |
| Cognitive Function | 0.1 | 0.2 | -1 |
| Colorectal Cancer | 0.2 | 0.2 | 0 |
| Constipation | 0.1 | 0.2 | -1 |
| Coronary artery disease | 0.3 | -0.3 | |
| COVID-19 | 0.2 | 0.3 | -0.5 |
| Crohn's Disease | 0.3 | 0.3 | 0 |
| Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
| cystic fibrosis | 0.2 | -0.2 | |
| deep vein thrombosis | 0 | 0.2 | 0 |
| Depression | 0.4 | 0.7 | -0.75 |
| Endometriosis | 0.1 | 0.2 | -1 |
| Epilepsy | 0.1 | 0.1 | 0 |
| erectile dysfunction | 0.1 | 0.1 | |
| Fibromyalgia | 0.2 | 0.1 | 1 |
| Functional constipation / chronic idiopathic constipation | 0.1 | 0.3 | -2 |
| gallstone disease (gsd) | 0.2 | -0.2 | |
| Generalized anxiety disorder | 0.2 | 0.1 | 1 |
| Gout | 0.2 | 0 | 0 |
| Graves' disease | 0.1 | 0.2 | -1 |
| Gulf War Syndrome | 0 | 0 | |
| Halitosis | 0.1 | 0.1 | |
| Hashimoto's thyroiditis | 0.2 | 0.1 | 1 |
| Heart Failure | 0.1 | 0.2 | -1 |
| Hidradenitis Suppurativa | 0.1 | 0.1 | |
| High Histamine/low DAO | 0.2 | 0.2 | |
| hyperglycemia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 0.1 | 0.6 | -5 |
| Hypothyroidism | 0.1 | -0.1 | |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0.1 | 0.2 | -1 |
| Inflammatory Bowel Disease | 0.5 | 0.3 | 0.67 |
| Insomnia | 0.1 | 0.2 | -1 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.1 | 0 | 0 |
| Irritable Bowel Syndrome | 0.2 | 0.3 | -0.5 |
| ischemic stroke | 0.1 | 0.2 | -1 |
| Liver Cirrhosis | 0.6 | 0.3 | 1 |
| Long COVID | 0.2 | 0.3 | -0.5 |
| Low bone mineral density | 0.2 | -0.2 | |
| Mast Cell Issues / mastitis | 0 | 0 | |
| ME/CFS with IBS | 0.1 | -0.1 | |
| ME/CFS without IBS | 0.1 | 0.1 | 0 |
| Menopause | 0.2 | -0.2 | |
| Metabolic Syndrome | 0.3 | 0.6 | -1 |
| Mood Disorders | 0.4 | 0.4 | 0 |
| Multiple Sclerosis | 0.1 | 0.3 | -2 |
| Multiple system atrophy (MSA) | 0.3 | 0.3 | |
| myasthenia gravis | 0.2 | -0.2 | |
| neuropathic pain | 0 | 0.6 | 0 |
| Neuropathy (all types) | 0 | 0.2 | 0 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.2 | 0.3 | -0.5 |
| NonCeliac Gluten Sensitivity | 0.1 | 0.1 | 0 |
| Obesity | 0.6 | 0.3 | 1 |
| obsessive-compulsive disorder | 0.1 | 0.1 | 0 |
| Osteoarthritis | 0.1 | 0.1 | 0 |
| Osteoporosis | 0.3 | 0.1 | 2 |
| Parkinson's Disease | 0.3 | 0.5 | -0.67 |
| Polycystic ovary syndrome | 0.3 | 0.2 | 0.5 |
| Postural orthostatic tachycardia syndrome | 0 | 0 | |
| Primary sclerosing cholangitis | 0.1 | 0 | 0 |
| Psoriasis | 0.3 | -0.3 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.3 | 0.3 | 0 |
| Rosacea | 0.2 | -0.2 | |
| Schizophrenia | 0.2 | 0.3 | -0.5 |
| scoliosis | 0 | 0 | |
| Sjögren syndrome | 0.1 | -0.1 | |
| Sleep Apnea | 0 | 0.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.1 | 0.1 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
| Stress / posttraumatic stress disorder | 0.2 | 0.4 | -1 |
| Systemic Lupus Erythematosus | 0.2 | 0.4 | -1 |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 0.1 | 0.2 | -1 |
| Type 2 Diabetes | 0.3 | 0.3 | 0 |
| Ulcerative colitis | 0.1 | 0.6 | -5 |
| Unhealthy Ageing | 0.2 | 0.2 | 0 |
| Vitiligo | 0.1 | 0.1 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
